MiR-181b suppresses angiogenesis by directly targeting cellular communication network factor 1

miR-181b inhibits HUVEC migration and tube formation in vitro, and suppresses perfusion recovery in a hindlimb ischemia animal model and in a capillary density assay. Cellular communication network factor 1 (CCN1) is a direct target of miR-181b. miR-181b suppresses angiogenesis at least in part by targeting CCN1 to inhibit the AMPK signaling pathway. Angiogenesis is essential for various physiological and pathological processes. Previous studies have shown that miRNAs play an important role in blood vessel development and angiogenesis. Recent studies have suggested that miR-181b might be involved in the regulation of angiogenesis in tumors. However, whether miR-181b plays a role in angiogenesis in nontumor diseases is unclear. We found that miR-181b expression was downregulated in hypoxia-stimulated primary human umbilical vein endothelial cells (HUVECs) and a mouse hindlimb ischemia (HLI) model. Gain- and loss-of-function studies showed that a miR-181b mimic inhibited HUVEC migration and tube formation in vitro, and a miR-181b inhibitor had the opposite effects. In vivo, agomir-181b suppressed perfusion recovery in the HLI model and capillary density in a Matrigel plug assay, while perfusion recovery and capillary density were increased by injection of antagomir-181b. Mechanistically, we showed with a reporter assay that cellular communication network factor 1 (CCN1) was a direct target of miR-181b. Moreover, miR-181b suppressed angiogenesis at least in part by targeting CCN1 to inhibit the AMPK signaling pathway. Our research suggests that miR-181b suppresses angiogenesis by directly targeting CCN1, which provides new clues for pro-angiogenic treatment strategies.

Automated summary

miR-181b inhibits angiogenesis by targeting CCN1 to suppress the AMPK signaling pathway, providing new insights for the development of pro-angiogenic treatment strategies.